JP2008036521A - 水中の溶存水素を活性化および安定化する方法 - Google Patents
水中の溶存水素を活性化および安定化する方法 Download PDFInfo
- Publication number
- JP2008036521A JP2008036521A JP2006213475A JP2006213475A JP2008036521A JP 2008036521 A JP2008036521 A JP 2008036521A JP 2006213475 A JP2006213475 A JP 2006213475A JP 2006213475 A JP2006213475 A JP 2006213475A JP 2008036521 A JP2008036521 A JP 2008036521A
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- water
- dissolved
- hydrogen molecules
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000001257 hydrogen Substances 0.000 title claims abstract description 183
- 229910052739 hydrogen Inorganic materials 0.000 title claims abstract description 183
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 title claims abstract description 160
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000003213 activating effect Effects 0.000 title claims abstract description 22
- 230000000087 stabilizing effect Effects 0.000 title claims abstract description 22
- -1 hydrogen ions Chemical class 0.000 claims abstract description 67
- 150000007524 organic acids Chemical class 0.000 claims abstract description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 24
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000007789 gas Substances 0.000 claims description 13
- 239000010949 copper Substances 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 229910052742 iron Inorganic materials 0.000 claims description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 10
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 229910052802 copper Inorganic materials 0.000 claims description 10
- 229910052748 manganese Inorganic materials 0.000 claims description 10
- 239000011572 manganese Substances 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- 239000011573 trace mineral Substances 0.000 claims description 9
- 235000013619 trace mineral Nutrition 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000001569 carbon dioxide Substances 0.000 claims description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 8
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 7
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000883 anti-obesity agent Substances 0.000 claims description 4
- 229940125710 antiobesity agent Drugs 0.000 claims description 4
- 238000005868 electrolysis reaction Methods 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 2
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000003405 preventing effect Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 description 30
- 229910052760 oxygen Inorganic materials 0.000 description 30
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000005416 organic matter Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 208000023584 Alzheimer disease 10 Diseases 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000001247 metal acetylides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/46104—Devices therefor; Their operating or servicing
- C02F1/4618—Devices therefor; Their operating or servicing for producing "ionised" acidic or basic water
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/20—Treatment of water, waste water, or sewage by degassing, i.e. liberation of dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/46—Treatment of water, waste water, or sewage by electrochemical methods
- C02F1/461—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
- C02F1/467—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
- C02F1/4676—Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electroreduction
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/66—Treatment of water, waste water, or sewage by neutralisation; pH adjustment
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2201/00—Apparatus for treatment of water, waste water or sewage
- C02F2201/46—Apparatus for electrochemical processes
- C02F2201/461—Electrolysis apparatus
- C02F2201/46105—Details relating to the electrolytic devices
- C02F2201/46115—Electrolytic cell with membranes or diaphragms
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2201/00—Apparatus for treatment of water, waste water or sewage
- C02F2201/46—Apparatus for electrochemical processes
- C02F2201/461—Electrolysis apparatus
- C02F2201/46105—Details relating to the electrolytic devices
- C02F2201/4618—Supplying or removing reactants or electrolyte
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2201/00—Apparatus for treatment of water, waste water or sewage
- C02F2201/46—Apparatus for electrochemical processes
- C02F2201/461—Electrolysis apparatus
- C02F2201/46105—Details relating to the electrolytic devices
- C02F2201/46195—Cells containing solid electrolyte
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/22—O2
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/30—H2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/32—Hydrogen storage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hydrology & Water Resources (AREA)
- Electrochemistry (AREA)
- Birds (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
【解決手段】水素イオンを共存させることを特徴とする水中の溶存水素分子を活性化および安定化する方法。
【選択図】なし
Description
2O2 -+2H+→O2+H2O2 (1)
Fe2++H2O2→Fe3++HO-+HO・ (2)
Cu1++H2O2→Cu2++HO-+HO・ (3)
2.酵素活性の低下:酵素蛋白が酸化変性すると、酵素活性が低下し、細胞の機能が低下する。
3.動脈硬化、心筋梗塞、脳梗塞の発症:酸化LDLは血管内皮細胞を障害し動脈硬化を来たしたり、血栓を作りやすい体質になる。
4.発癌:すべての活性酸素は核酸を障害する。細胞は、DNAが酸化され、障害を受けると癌化したり、細胞死にいたる。
5.老化の促進
6.寿命の短縮
7.白内障
8.皮膚のシミ
9.アルツハイマー病
10.腎障害
11.レドックス制御:活性酸素は最終的にインスリン分泌抑制に作用し、糖尿病等の原因となる。
(1) 水素イオンを共存させることを特徴とする水中の溶存水素分子を活性化および安定化する方法。
(2) 水に有機酸を溶解して解離して水素イオンを生成させることを特徴とする1項に記載の溶存水素分子を活性化および安定化する方法。
(3) 水に炭酸ガスを溶解して解離して水素イオンを生成させることを特徴とする1項に記載の溶存水素分子を活性化および安定化する方法。
(4) 水に水素ガスを吹き込んで水素分子を溶解させることを特徴とする1項に記載の溶存水素分子を活性化および安定化する方法。
(5) 有機酸が溶解した酸性の水溶液をカソード電解し、電解により水素分子を生成し、水素分子と水素イオンを共存させることを特徴とする1項に記載の溶存水素分子を活性化および安定化する方法。
(6) アノード室とカソ−ド室の間に中間室を設けた三室型電解槽を用いて中間室に有機酸が溶解した酸性の水溶液を供給して水素分子を生成させ、水素イオンを共存させることを特徴とする1項に記載の溶存水素分子を活性化および安定化する方法。
(7) 水を脱気し、水素分子と水素イオンを共存させることを特徴とする1項ないし6項のいずれか1項に記載の溶存水素分子を活性化および安定化する方法。
(8) 水素分子濃度が0.1ppm以上であることを特徴とする1項ないし7項のいずれか1項に記載の溶存水素分子を活性化および安定化する方法。
(9) 水素イオン濃度が10−7M以上であることを特徴とする1項ないし8項のいずれか1項に記載の溶存水素分子を活性化および安定化する方法。
(10) 水素分子と水素イオンを共存させた水、水素ガスおよび炭酸ガスが耐圧容器に充填されことを特徴とする活性水素分子溶解水の保存容器。
(11) 水素分子と水素イオンを共存させた水、水素ガスおよび窒素ガスが耐圧容器に充填されことを特徴とする活性水素分子溶解水の保存容器。
(12) 水素分子および水素イオンを共存させた水を充填した耐圧性の水タンクと、パイプを介して水素ガスと炭酸ガスまたは水素ガスと窒素ガスを該水タンクに圧入するためのガスボンベと、該水タンクから水素分子および水素イオンを共存させた水を供給するための供給用パイプからなることを特徴とする活性水素分子溶解水の供給装置。
(13) 水素分子および水素イオンを共存させた水を含むことを特徴とする活性酸素除去剤。
(14) 水素分子および水素イオンを共存させた水を含むことを特徴とする血圧降下剤。
(15) 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする14項に記載の血圧降下剤。
(16) 水素分子および水素イオンを共存させた水を含むことを特徴とする血糖値低下剤。
(17) 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする16項に記載の血糖値低下剤。
(18) 水素分子および水素イオンを共存させた水を含むことを特徴とする肌状態改善剤。
(19) 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする18項に記載の肌状態改善剤。
(20) 水素分子および水素イオンを共存させた水を含むことを特徴とする肥満防止剤。
(21) 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする20項に記載の血圧降下剤。
血圧降下剤、血糖値低下剤、肌状態改善剤、肥満防止剤としての用途が期待できる。さらに微量元素である鉄、亜鉛、銅、マンガン等を添加して活性酸素除去効率、血圧降下効果、血糖値低下効果、肥満防止効果を向上させることが期待できる。鉄、亜鉛および銅は活性酸素除去機能を有する酵素を活性化することが知られている。また、マンガンは動脈硬化改善効果をもたらす事が報告されている。
39 カソード室
41 アノード室
49 カソード室
51 中間室
75 カソード室
76 アノード室
86 カソード室
87 中間室
88 アノード室
Claims (21)
- 水素イオンを共存させることを特徴とする水中の溶存水素分子を活性化および安定化する方法。
- 水に有機酸を溶解して解離して水素イオンを生成させることを特徴とする請求項1に記載の溶存水素分子を活性化および安定化する方法。
- 水に炭酸ガスを溶解して解離して水素イオンを生成させることを特徴とする請求項1に記載の溶存水素分子を活性化および安定化する方法。
- 水に水素ガスを吹き込んで水素分子を溶解させることを特徴とする請求項1に記載の溶存水素分子を活性化および安定化する方法。
- 有機酸が溶解した酸性の水溶液をカソード電解し、電解により水素分子を生成し、水素分子と水素イオンを共存させることを特徴とする請求項1に記載の溶存水素分子を活性化および安定化する方法。
- アノード室とカソ−ド室の間に中間室を設けた三室型電解槽を用いて中間室に有機酸が溶解した酸性の水溶液を供給して水素分子を生成させ、水素イオンを共存させることを特徴とする請求項1に記載の溶存水素分子を活性化および安定化する方法。
- 水を脱気し、水素分子と水素イオンを共存させることを特徴とする請求項1ないし6のいずれか1項に記載の溶存水素分子を活性化および安定化する方法。
- 水素分子濃度が0.1ppm以上であることを特徴とする請求項1ないし7のいずれか1項に記載の溶存水素分子を活性化および安定化する方法。
- 水素イオン濃度が10−7M以上であることを特徴とする請求項1ないし8のいずれか1項に記載の溶存水素分子を活性化および安定化する方法。
- 水素分子と水素イオンを共存させた水、水素ガスおよび炭酸ガスが耐圧容器に充填されことを特徴とする活性水素分子溶解水の保存容器。
- 水素分子と水素イオンを共存させた水、水素ガスおよび窒素ガスが耐圧容器に充填されことを特徴とする活性水素分子溶解水の保存容器。
- 水素分子および水素イオンを共存させた水を充填した耐圧性の水タンクと、パイプを介して水素ガスと炭酸ガスまたは水素ガスと窒素ガスを該水タンクに圧入するためのガスボンベと、該水タンクから水素分子および水素イオンを共存させた水を供給するための供給用パイプからなることを特徴とする活性水素分子溶解水の供給装置。
- 水素分子および水素イオンを共存させた水を含むことを特徴とする活性酸素除去剤。
- 水素分子および水素イオンを共存させた水を含むことを特徴とする血圧降下剤。
- 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする請求項14に記載の血圧降下剤。
- 水素分子および水素イオンを共存させた水を含むことを特徴とする血糖値低下剤。
- 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする請求項16に記載の血糖値低下剤。
- 水素分子および水素イオンを共存させた水を含むことを特徴とする肌状態改善剤。
- 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする請求項18に記載の肌状態改善剤。
- 水素分子および水素イオンを共存させた水を含むことを特徴とする肥満
防止剤。 - 鉄、亜鉛、銅およびマンガンからなる群より選ばれる必須微量元素をさらに溶解したことを特徴とする請求項20に記載の肥満防止剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006213475A JP5134793B2 (ja) | 2006-08-04 | 2006-08-04 | 水中の溶存水素を活性化および安定化する方法 |
CN2011100796188A CN102247402A (zh) | 2006-08-04 | 2007-07-05 | 一种活性氧清除剂、降血压的药、降血糖的药、皮肤调理剂和减肥的药 |
CN2007800250683A CN101484391B (zh) | 2006-08-04 | 2007-07-05 | 活化并稳定溶解在水中的氢的方法 |
US12/308,379 US8562860B2 (en) | 2006-08-04 | 2007-07-05 | Method for activating and stabilizing dissolved hydrogen in water |
CN2011100796065A CN102249041A (zh) | 2006-08-04 | 2007-07-05 | 溶解有活性氢分子的水的储存容器和供给装置 |
PCT/JP2007/063420 WO2008015867A1 (fr) | 2006-08-04 | 2007-07-05 | Procédé d'activation et de stabilisation d'hydrogène dissous dans de l'eau |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006213475A JP5134793B2 (ja) | 2006-08-04 | 2006-08-04 | 水中の溶存水素を活性化および安定化する方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012226618A Division JP2013047242A (ja) | 2012-10-12 | 2012-10-12 | 活性酸素除去剤、血圧降下剤、血糖値低下剤、肌状態改善剤および肥満防止剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008036521A true JP2008036521A (ja) | 2008-02-21 |
JP5134793B2 JP5134793B2 (ja) | 2013-01-30 |
Family
ID=38997049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006213475A Active JP5134793B2 (ja) | 2006-08-04 | 2006-08-04 | 水中の溶存水素を活性化および安定化する方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8562860B2 (ja) |
JP (1) | JP5134793B2 (ja) |
CN (3) | CN102249041A (ja) |
WO (1) | WO2008015867A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008156320A (ja) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
JP2009228044A (ja) * | 2008-03-21 | 2009-10-08 | Kurita Water Ind Ltd | 水素含有ガスの処理方法 |
WO2010044272A1 (ja) * | 2008-10-17 | 2010-04-22 | 有限会社スプリング | 溶存水素飲料水の製造装置及びその製造方法 |
JP2010240376A (ja) * | 2009-03-13 | 2010-10-28 | Mizu Kk | 水素含有生体適用液の製造方法、及びそのための装置 |
JP2013094693A (ja) * | 2011-10-28 | 2013-05-20 | Spring:Kk | 溶存水素濃度を高めた水素水の製造装置および該水素水の製造方法 |
WO2016035288A1 (ja) * | 2014-09-01 | 2016-03-10 | 株式会社日本トリム | 農業用電解水生成装置および農業用電解水 |
JP2017079606A (ja) * | 2015-10-23 | 2017-05-18 | 光騰光電股▲ふん▼有限公司 | 抗酸化機能性飲料、及び抗酸化機能性飲料の製造方法 |
JP2017087087A (ja) * | 2015-11-02 | 2017-05-25 | 国立研究開発法人日本原子力研究開発機構 | 水素水製造装置 |
CN113631083A (zh) * | 2019-03-08 | 2021-11-09 | 格勒诺布尔-阿尔卑斯大学 | 用于测量治疗依从性的组合物及其方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009026622A1 (de) * | 2009-05-29 | 2010-12-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Formkörper mit eingebetteten Kopplungspartikeln für Biomoleküle |
WO2011036822A1 (en) * | 2009-09-28 | 2011-03-31 | Tomoaki Yoshioka | A method to promote hydrogen bond and the water molecular bond of the human body |
WO2013051810A2 (en) * | 2011-10-05 | 2013-04-11 | Samsung Electronics Co., Ltd. | Apparatus for producing reducing water |
CN106793807A (zh) * | 2014-05-12 | 2017-05-31 | 海吉知识产权公司 | 包含氢的组合物 |
JP6333628B2 (ja) * | 2014-05-28 | 2018-05-30 | 株式会社スイソサム | 水素水生成装置 |
CN106389462A (zh) * | 2016-04-10 | 2017-02-15 | 北京工业大学 | 至少包含氢分子的液体/气体在制备抗原发性肝癌药物中的应用 |
JP6169762B1 (ja) * | 2016-08-02 | 2017-07-26 | MiZ株式会社 | 水素水の生成方法 |
AU2020200706A1 (en) * | 2019-02-04 | 2020-08-20 | Hydrogen4Health Pty Ltd | Hydrogen-based compositions |
HUP1900397A1 (hu) * | 2019-11-22 | 2021-05-28 | Simon Laszlo Pal Dr | Szén dioxid gázzal alacsony nyomáson, hidrogén gázzal nagy nyomáson szaturált, üvegben vagy egyéb speciális anyagú flakonban robbanásveszélymentesen, a teret légmentesen kitöltve és diffúziómentesen palackozott... |
CN112811560A (zh) * | 2021-01-19 | 2021-05-18 | 宁波上下生物科技发展有限公司 | 牛磺酸作为氢气逸散延缓剂的应用、富氢水及其制备方法 |
US11465925B1 (en) * | 2022-01-13 | 2022-10-11 | Heimdal Limited | Carbon capture method and system |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10296262A (ja) * | 1997-04-22 | 1998-11-10 | Atsushi Kitada | 特殊電解水素水 |
JPH1177048A (ja) * | 1997-09-11 | 1999-03-23 | Takao Miyauchi | 活性水素水の製造装置 |
JP2002301483A (ja) * | 2001-04-06 | 2002-10-15 | Shigemi Iida | 水素水製造装置 |
JP2002361250A (ja) * | 2001-06-12 | 2002-12-17 | San Waaku:Kk | 活性水素含有水の製法 |
JP2002370091A (ja) * | 2001-06-13 | 2002-12-24 | Aqua Science:Kk | 生体水に類似する水およびその製造法 |
JP2003095915A (ja) * | 2001-09-25 | 2003-04-03 | Shiseido Co Ltd | 皮膚外用組成物 |
WO2004039735A1 (ja) * | 2002-04-26 | 2004-05-13 | Miz Co., Ltd. | 抗酸化方法、抗酸化機能水およびその用途 |
JP2005065620A (ja) * | 2003-08-26 | 2005-03-17 | Suzuran:Kk | 機能性水 |
JP2005177724A (ja) * | 2003-12-16 | 2005-07-07 | Hiroshima Kasei Ltd | 水素水を製造する装置 |
JP2005342645A (ja) * | 2004-06-04 | 2005-12-15 | Mikuni Corp | 電解水の製造方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55160028A (en) * | 1979-05-31 | 1980-12-12 | Asahi Chem Ind Co Ltd | Improved fluorinated cation exchange membrane and production thereof |
JP3181796B2 (ja) * | 1994-10-28 | 2001-07-03 | 日本電気株式会社 | 電解水製造装置 |
JP3791311B2 (ja) * | 1998-11-25 | 2006-06-28 | 松下電工株式会社 | 電解水生成装置 |
DE19854783C1 (de) * | 1998-11-27 | 2000-05-18 | Bernhard Boeckenhoff | Verfahren zum Verpacken und haltbaren Lagern von erntefrischem Spargel |
CN1078157C (zh) * | 1999-05-10 | 2002-01-23 | 李羽堃 | 一种速溶饮料保鲜的灌装工艺方法 |
CA2452682A1 (en) * | 2001-06-29 | 2003-01-09 | Miz Co., Ltd. | Method for antioxidation and antioxidative functional water |
CN2509110Y (zh) * | 2001-11-01 | 2002-09-04 | 黄庆杰 | 带有加气装置的微型鲜啤酒周转桶 |
KR100419536B1 (ko) * | 2001-11-02 | 2004-02-19 | 강송식 | 전기분해 정수기 |
JP4653945B2 (ja) * | 2003-10-24 | 2011-03-16 | ミズ株式会社 | 薬理機能水、およびその用途 |
WO2006003192A1 (en) * | 2004-07-06 | 2006-01-12 | Shell Internationale Research Maatschappij B.V. | Container for storing liquefied gas |
-
2006
- 2006-08-04 JP JP2006213475A patent/JP5134793B2/ja active Active
-
2007
- 2007-07-05 CN CN2011100796065A patent/CN102249041A/zh active Pending
- 2007-07-05 CN CN2007800250683A patent/CN101484391B/zh not_active Expired - Fee Related
- 2007-07-05 US US12/308,379 patent/US8562860B2/en active Active
- 2007-07-05 CN CN2011100796188A patent/CN102247402A/zh active Pending
- 2007-07-05 WO PCT/JP2007/063420 patent/WO2008015867A1/ja active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10296262A (ja) * | 1997-04-22 | 1998-11-10 | Atsushi Kitada | 特殊電解水素水 |
JPH1177048A (ja) * | 1997-09-11 | 1999-03-23 | Takao Miyauchi | 活性水素水の製造装置 |
JP2002301483A (ja) * | 2001-04-06 | 2002-10-15 | Shigemi Iida | 水素水製造装置 |
JP2002361250A (ja) * | 2001-06-12 | 2002-12-17 | San Waaku:Kk | 活性水素含有水の製法 |
JP2002370091A (ja) * | 2001-06-13 | 2002-12-24 | Aqua Science:Kk | 生体水に類似する水およびその製造法 |
JP2003095915A (ja) * | 2001-09-25 | 2003-04-03 | Shiseido Co Ltd | 皮膚外用組成物 |
WO2004039735A1 (ja) * | 2002-04-26 | 2004-05-13 | Miz Co., Ltd. | 抗酸化方法、抗酸化機能水およびその用途 |
JP2005065620A (ja) * | 2003-08-26 | 2005-03-17 | Suzuran:Kk | 機能性水 |
JP2005177724A (ja) * | 2003-12-16 | 2005-07-07 | Hiroshima Kasei Ltd | 水素水を製造する装置 |
JP2005342645A (ja) * | 2004-06-04 | 2005-12-15 | Mikuni Corp | 電解水の製造方法 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008156320A (ja) * | 2006-12-26 | 2008-07-10 | Hydrox Kk | 抗酸化性機能水 |
JP2009228044A (ja) * | 2008-03-21 | 2009-10-08 | Kurita Water Ind Ltd | 水素含有ガスの処理方法 |
US8518225B2 (en) | 2008-10-17 | 2013-08-27 | Spring Co., Ltd. | Apparatus and method for producing hydrogen-dissolved drinking water |
WO2010044272A1 (ja) * | 2008-10-17 | 2010-04-22 | 有限会社スプリング | 溶存水素飲料水の製造装置及びその製造方法 |
AU2009304917B2 (en) * | 2008-10-17 | 2014-01-16 | Spring Co., Ltd. | Apparatus for producing hydrogen-dissolved drinking water and process for producing the dissolved drinking water |
JP2010240376A (ja) * | 2009-03-13 | 2010-10-28 | Mizu Kk | 水素含有生体適用液の製造方法、及びそのための装置 |
JP2013094693A (ja) * | 2011-10-28 | 2013-05-20 | Spring:Kk | 溶存水素濃度を高めた水素水の製造装置および該水素水の製造方法 |
WO2016035288A1 (ja) * | 2014-09-01 | 2016-03-10 | 株式会社日本トリム | 農業用電解水生成装置および農業用電解水 |
CN106604895A (zh) * | 2014-09-01 | 2017-04-26 | 日本多宁股份有限公司 | 农用电解水生成装置及农用电解水 |
JPWO2016035288A1 (ja) * | 2014-09-01 | 2017-07-13 | 株式会社日本トリム | 農業用電解水生成装置および農業用電解水 |
CN106604895B (zh) * | 2014-09-01 | 2020-08-04 | 日本多宁股份有限公司 | 农用电解水生成装置及农用电解水 |
US11279635B2 (en) | 2014-09-01 | 2022-03-22 | Nihon Trim Co., Ltd. | Method of using an agricultural electrolyzed water-generating apparatus for generation of agricultural electrolyzed water useful for plant growth |
JP2017079606A (ja) * | 2015-10-23 | 2017-05-18 | 光騰光電股▲ふん▼有限公司 | 抗酸化機能性飲料、及び抗酸化機能性飲料の製造方法 |
JP2017087087A (ja) * | 2015-11-02 | 2017-05-25 | 国立研究開発法人日本原子力研究開発機構 | 水素水製造装置 |
CN113631083A (zh) * | 2019-03-08 | 2021-11-09 | 格勒诺布尔-阿尔卑斯大学 | 用于测量治疗依从性的组合物及其方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101484391A (zh) | 2009-07-15 |
WO2008015867A1 (fr) | 2008-02-07 |
US20090311342A1 (en) | 2009-12-17 |
US8562860B2 (en) | 2013-10-22 |
CN102249041A (zh) | 2011-11-23 |
CN102247402A (zh) | 2011-11-23 |
JP5134793B2 (ja) | 2013-01-30 |
CN101484391B (zh) | 2013-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5134793B2 (ja) | 水中の溶存水素を活性化および安定化する方法 | |
JP4272054B2 (ja) | 抗酸化方法、および抗酸化機能水 | |
RU2492146C2 (ru) | Способ обогащения воды кислородом посредством электролитического процесса, вода или напиток, обогащенные кислородом, и их применение | |
JP4004523B1 (ja) | 透析液調製用水およびそれを用いた透析液、透析液の製造方法ならびに透析装置 | |
JP5361325B2 (ja) | 溶存水素飲料水の製造装置及びその製造方法 | |
JP3569270B2 (ja) | コロイド含有電解還元水およびその製造方法 | |
JP2005296794A (ja) | 水素還元水の製造方法 | |
TW200835653A (en) | Functional water and process for producing the same | |
JPWO2006103789A1 (ja) | 酸素含有還元性水性飲料及びその製造方法 | |
JP5918966B2 (ja) | 溶存水素濃度を高めた水素水の製造装置 | |
Lapin et al. | Biochemical effects of molecular hydrogen in aqueous systems | |
CN108823053A (zh) | 一种加速黄酒陈化的方法 | |
JP2013047242A (ja) | 活性酸素除去剤、血圧降下剤、血糖値低下剤、肌状態改善剤および肥満防止剤 | |
JP2007253131A (ja) | 抗酸化剤を含有する機能水 | |
JP5893939B2 (ja) | オゾン水生成装置及びオゾン水生成方法 | |
CN108841558A (zh) | 一种快速陈化黄酒的方法 | |
CN105668894A (zh) | 一种小分子团弱碱性负氢好水的制备工艺 | |
JPH091153A (ja) | 導電体表面で活性化した水素を用いた溶存酸素の除去法 | |
JPWO2006051588A1 (ja) | 還元性飲料及びその製造方法 | |
CN108751377A (zh) | 一种生产负电位水的装置及方法 | |
TWI270532B (en) | Method for antioxidation and antioxidative functional water | |
WO2003095373A1 (fr) | Eau contenant de l'hydrogene actif et son procede de production | |
JP2007000750A (ja) | 活性酸素消去剤、及び活性酸素消去剤の製造方法 | |
JP2005270938A (ja) | 水素濃縮水の製造方法および水素濃縮水 | |
KR100658409B1 (ko) | 양극 전해수 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121012 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121106 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121112 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151116 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5134793 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |